J&J goes back to Ionis for its second experimental pill for a GI autoimmune disease
Almost three years after J&J $JNJ handed over $35 million in cash and promised up to $800 million in milestones to cozy up to the antisense research team at Ionis, the pharma giant has stepped back up for its second RNA development deal.
J&J is spending $5 million to bag rights to IONIS-JBI2-2.5Rx, which now goes into their gastrointestinal pipeline for autoimmune disease, though the companies are keeping the target under wraps for now.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
